Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.

PURPOSE Acute pancreatitis is one of the common causes of asparaginase intolerance. The mechanism is unknown, and genetic predisposition to asparaginase-induced pancreatitis has not been previously identified. METHODS To determine clinical risk factors for asparaginase-induced pancreatitis, we studied a cohort of 5,185 children and young adults with acute lymphoblastic leukemia, including 117 (2.3%) who were diagnosed with at least one episode of acute pancreatitis during therapy. A genome-wide association study was performed in the cohort and in an independent case-control group of 213 patients to identify genetic risk factors. RESULTS Risk factors associated with pancreatitis included genetically defined Native American ancestry (P < .001), older age (P < .001), and higher cumulative dose of asparaginase (P < .001). No common variants reached genome-wide significance in the genome-wide association study, but a rare nonsense variant rs199695765 in CPA2, encoding carboxypeptidase A2, was highly associated with pancreatitis (hazard ratio, 587; 95% CI, 66.8 to 5166; P = 9.0 × 10(-9)). A gene-level analysis showed an excess of additional CPA2 variants in patients who did versus those who did not develop pancreatitis (P = .001). Sixteen CPA2 single-nucleotide polymorphisms were associated (P < .05) with pancreatitis, and 13 of 24 patients who carried at least one of these variants developed pancreatitis. Biologic functions that were overrepresented by common variants modestly associated with pancreatitis included purine metabolism and cytoskeleton regulation. CONCLUSION Older age, higher exposure to asparaginase, and higher Native American ancestry were independent risk factors for pancreatitis in patients with acute lymphoblastic leukemia. Those who inherit a nonsense rare variant in the CPA2 gene had a markedly increased risk of asparaginase-induced pancreatitis.

[1]  M. Loh,et al.  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.

[2]  M. Tremelling,et al.  HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants , 2014, Nature Genetics.

[3]  R. Wade,et al.  Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. , 2014, The Lancet. Oncology.

[4]  K. Schmiegelow,et al.  Asparaginase‐associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol , 2014, British journal of haematology.

[5]  John Baillie,et al.  American College of Gastroenterology Guidelines: Management of Acute Pancreatitis , 2013 .

[6]  D. Whitcomb,et al.  Genetics of acute and chronic pancreatitis , 2013, Current opinion in gastroenterology.

[7]  R. Wade,et al.  Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2013, British journal of haematology.

[8]  H. Friess,et al.  Variants in CPA1 are strongly associated with early onset chronic pancreatitis , 2013, Nature Genetics.

[9]  F. Madanat,et al.  6-Mercaptopurine-induced recurrent acute pancreatitis in children with acute lymphoblastic leukemia/lymphoma. , 2013, Journal of pediatric hematology/oncology.

[10]  Iuliana Ionita-Laza,et al.  Sequence kernel association tests for the combined effect of rare and common variants. , 2013, American journal of human genetics.

[11]  J. Lagergren,et al.  Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. , 2013, JAMA internal medicine.

[12]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robert C. Green,et al.  Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis , 2012, Nature Genetics.

[14]  K. Schmiegelow,et al.  Asparaginase‐associated pancreatitis in children , 2012, British journal of haematology.

[15]  T. Frick.  The role of calcium in acute pancreatitis. , 2012, Surgery.

[16]  W. Lowther,et al.  Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[17]  D. Neuberg,et al.  Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01 , 2011 .

[18]  M. Lieber,et al.  Non-MTC IGH-CCND1 Breakpoints in Mantle Cell Lymphoma Are Associated with CpG Sites and AID Hotspots , 2011 .

[19]  W. Haley,et al.  Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[20]  M. Loh,et al.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia , 2011, Nature Genetics.

[21]  C. Charon,et al.  Mutations in DHDPSL are responsible for primary hyperoxaluria type III. , 2010, American journal of human genetics.

[22]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[23]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[24]  S. Hunger,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.

[25]  H. Sather,et al.  Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group Study CCG-1961 , 2008 .

[26]  D. Flockhart,et al.  Predicting asparaginase‐associated pancreatitis , 2007, Pediatric blood & cancer.

[27]  M. Sahin-Tóth,et al.  Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht's enzyme Y , 2007, Proceedings of the National Academy of Sciences.

[28]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[29]  F. Schmitz,et al.  Mutations in the calcium-sensing receptor: A new genetic risk factor for chronic pancreatitis? , 2006, Scandinavian journal of gastroenterology.

[30]  C. Pitchumoni,et al.  Drug-Induced Pancreatitis: An Update , 2005, Journal of clinical gastroenterology.

[31]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[32]  F. Schmitz,et al.  A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations , 2003, BMC gastroenterology.

[33]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[34]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[35]  Olfert Landt,et al.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis , 2000, Nature Genetics.

[36]  O. Alvarez,et al.  Pegaspargase-induced pancreatitis. , 2000, Medical and pediatric oncology.

[37]  M. Schwarz,et al.  Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. , 1998, The New England journal of medicine.

[38]  M. Billeter,et al.  The Sequence and Conformation of Human Pancreatic Procarboxypeptidase A2 , 1995, The Journal of Biological Chemistry.

[39]  L. Ferrell,et al.  Pancreatic exocrine secretion in acute experimental pancreatitis. , 1990, Gastroenterology.

[40]  John D. Kalbfleisch,et al.  The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.

[41]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[42]  R. Baehner,et al.  Latent onset of clinical pancreatitis in children receiving l‐asparaginase therapy , 1974, Cancer.

[43]  Alexander Schneider,et al.  Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. , 2011, Gastroenterology.

[44]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[45]  Tsuman Vg,et al.  [Acute pancreatitis in children]. , 1995, Khirurgiia.

[46]  Y. Takeyama,et al.  Protective effect of a microtubule stabilizer taxol on caerulein-induced acute pancreatitis in rat. , 1992, The Journal of clinical investigation.

[47]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .